Caladrius Biosciences, Inc. (CLBS) Downgraded by Zacks Investment Research
Caladrius Biosciences, Inc. (NASDAQ:CLBS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday.
According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “
A number of other equities research analysts also recently weighed in on CLBS. HC Wainwright set a $7.00 price target on shares of Caladrius Biosciences and gave the company a “buy” rating in a research report on Friday, August 11th. ValuEngine upgraded shares of Caladrius Biosciences from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.
Caladrius Biosciences (NASDAQ:CLBS) traded down 0.28% during trading on Wednesday, reaching $3.58. The company’s stock had a trading volume of 19,805 shares. Caladrius Biosciences has a 52-week low of $2.65 and a 52-week high of $7.79. The firm’s 50-day moving average is $3.87 and its 200-day moving average is $4.36.
Caladrius Biosciences (NASDAQ:CLBS) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.08. Caladrius Biosciences had a negative net margin of 84.10% and a negative return on equity of 180.68%. Equities analysts expect that Caladrius Biosciences will post ($2.42) earnings per share for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CLBS. KCG Holdings Inc. raised its position in shares of Caladrius Biosciences by 74.6% in the first quarter. KCG Holdings Inc. now owns 36,291 shares of the biotechnology company’s stock valued at $183,000 after buying an additional 15,501 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Caladrius Biosciences by 34.3% in the first quarter. Renaissance Technologies LLC now owns 97,552 shares of the biotechnology company’s stock valued at $491,000 after buying an additional 24,900 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Caladrius Biosciences by 2.8% in the second quarter. Vanguard Group Inc. now owns 155,380 shares of the biotechnology company’s stock valued at $723,000 after buying an additional 4,163 shares in the last quarter. Institutional investors own 6.47% of the company’s stock.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Caladrius Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.